37 results on '"Kwon, Sun‐Hong"'
Search Results
2. Cost-effectiveness of improving patients’ adherence to tuberculosis treatment in South Korea using discrete event simulation
- Author
-
Min, Serim, Kwon, Sun-Hong, Lee, Eui-Kyung, and Nam, Jin Hyun
- Published
- 2024
- Full Text
- View/download PDF
3. Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis
- Author
-
Jang, Suk-Chan, Nam, Jin Hyun, Lee, Seung-Ah, An, Dasom, Kim, Hye-Lin, Kwon, Sun-Hong, and Lee, Eui-Kyung
- Published
- 2022
- Full Text
- View/download PDF
4. Adherence is an optimal factor for maximizing the effective and safe use of oral anticoagulants in patients with atrial fibrillation
- Author
-
Yang, So-Young, Kang, Dong-Won, Nam, Jin Hyun, Choi, Eue-Keun, Lee, Eui-Kyung, Shin, Ju-Young, and Kwon, Sun-Hong
- Published
- 2022
- Full Text
- View/download PDF
5. Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL).
- Author
-
Lee, Jeong Eun, Nam, Jin Hyun, Kwon, Sun Hong, Kim, Bo Kyung, and Ha, Seung Min
- Subjects
ANAPLASTIC lymphoma kinase ,PATIENT compliance ,ASIANS ,LUNG cancer ,OVERALL survival - Abstract
Purpose: There is a lack of real‐world data in Asian populations for brigatinib, a next‐generation anaplastic lymphoma kinase (ALK) inhibitor for patients with non‐small cell lung cancer (NSCLC). This study analysed real‐world outcomes and dosing patterns for brigatinib in patients with crizotinib‐refractory ALK+ NSCLC in South Korea. Methods: This retrospective, non‐interventional, cohort study used South Korean Health Insurance and Review Assessment claims data for adults with ALK+ NSCLC who initiated brigatinib between 19 April 2019 and 31 March 2021 after receiving prior crizotinib. Patients' characteristics, time to discontinuation (TTD), time to dose reduction, overall survival (OS) and treatment adherence were assessed. Results: The study included 174 patients (56.9% male; 27.0% with a history of brain metastases). Median duration of prior crizotinib was 17 (range 0.3–48) months. Median follow‐up after brigatinib initiation was 18 (range 0–34) months. Overall, 88.5% of patients received full‐dose brigatinib (180 mg/day) and 93.1% of patients were adherent (proportion of days covered ≥0.8). The median TTD was 24.9 months (95% CI 15.2–not reached). The probability of continuing treatment was 63.2% at 1 year and 51.5% at 2 years. The probability of continuing at full or peak dose was 79.7% at 1 year and 75.6% at 2 years. Median OS was not reached. The 2‐year OS rate was 68.7%. Conclusions: In this first nationwide retrospective study using national insurance claim data, brigatinib demonstrated real‐world clinical benefit as second‐line treatment after prior crizotinib in ALK+ NSCLC patients in South Korea. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Real-world effectiveness of CDK4/6 inhibitors on patients with HR+/HER2– advanced breast cancer in South Korea, focusing on underrepresented patients.
- Author
-
Jung, Hye-In, Kwon, Sun-Hong, Nam, Jin Hyun, Cho, Jeong-Yeon, and Lee, Eui-Kyung
- Subjects
- *
METASTATIC breast cancer , *CYCLIN-dependent kinase inhibitors , *CYCLIN-dependent kinases , *OLDER patients , *AGE groups , *AROMATASE inhibitors - Abstract
We assessed the real-world effectiveness of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors as first-line treatments in postmenopausal patients with HR+/HER2− advanced breast cancer, focusing on younger (<45 years) and older (>78 years) populations not considered in clinical trials. We analyzed nationwide claims data from the Health Insurance Review and Assessment Service between November 2016 and February 2021. In this retrospective cohort study, patients using CDK4/6 inhibitors and aromatase inhibitors were selected and grouped by age as follows: 45–78 years (trial-enrolled), <45 years (younger), and >78 years (older). We estimated the median real-world progression-free survival (rwPFS) and overall survival (OS) using the Kaplan-Meier method. We conducted Cox regression analysis using a sub-distribution hazard model to evaluate risk factors (age, history of prior systemic treatment, presence of metastasis, comorbidity index, and type of provider) and estimated hazard ratios (HR). Among the 2,830 patients who received CDK4/6 inhibitors as first-line therapy, we identified 358 (12.65%) younger and 148 (5.23%) older underrepresented patients. The younger patient group (50.84%) had the highest rate of prior systemic therapy, followed by the trial-enrolled (25.39%) and older patient groups (8.11%). The median rwPFS was shorter in the older group (19.30 months) than those in the younger and the trial-enrolled age groups (30.33 and 34.53 months, respectively; p =.002). The HR of older age for death was 1.59 (95% confidence interval (CI) = 1.24–2.03). For rwPFS, the HR of prior systemic therapy was 1.19 (95% CI = 1.04–1.37). The younger age group, which was underrepresented in the trial, did not show a significant difference in risk compared with the enrolled age group. However, the older age group, which was also underrepresented in the trial, faces a risk of mortality but not progression. Patients who fall outside the specified age groups for the clinical trial can still expect the same level of effectiveness in terms of progression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Cost-Effectiveness of Tiotropium in Elderly Patients with Severe Asthma Using Real-World Data
- Author
-
Hong, Sung-Hyun, Cho, Jeong-Yeon, Kim, Tae-Bum, Lee, Eui-Kyung, Kwon, Sun-Hong, and Shin, Ju-Young
- Published
- 2021
- Full Text
- View/download PDF
8. Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies
- Author
-
Kwon, Sun-Hong, Park, Hea-Sun, Na, Young-Jin, Park, Chul, Shin, Ju-Young, and Kim, Hye-Lin
- Published
- 2021
- Full Text
- View/download PDF
9. Cost‐effectiveness study of FIB‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at‐risk population.
- Author
-
Park, Huiyul, Yoon, Eileen L., Kim, Mimi, Kwon, Sun‐Hong, Kim, Donghee, Cheung, Ramsey, Kim, Hye‐Lin, and Jun, Dae Won
- Subjects
HEPATIC fibrosis ,MEDICAL screening ,FATTY liver ,CARDIOVASCULAR diseases ,COST effectiveness ,NON-alcoholic fatty liver disease ,MEDICAL care costs - Abstract
Background & Aims: The cost‐effectiveness to screen hepatic fibrosis in at‐risk population as recommended by several professional societies has been limited. This study aimed to investigate the cost‐effectiveness of this screening strategy in the expanded at‐risk population recently proposed by several societies. Methods: A combined model of the decision tree and Markov models was developed to compare expected costs, quality‐adjusted life‐years (QALYs) and incremental cost‐effectiveness ratio (ICER) between screening and no screening groups. The model included liver disease‐related health states and cardiovascular disease (CVD) states as a base‐case analysis. Screening strategy consisted of fibrosis‐4 index (FIB‐4) followed by vibration‐controlled transient elastography (VCTE) and intensive lifestyle intervention (ILI) as a treatment for diagnosed patients. Results: Cost‐effectiveness analysis showed that screening the at‐risk population entailed $298 incremental costs and an additional 0.0199 QALY per patient compared to no screening (ICER $14 949/QALY). Screening was cost‐effective based on the implicit ICER threshold of $25 000/QALY in Korea. When the effects of ILI on CVD and extrahepatic malignancy were incorporated into the cost‐effectiveness model, the ICER decreased by 0.85 times from the base‐case analysis (ICER $12 749/QALY). In contrast, when only the effects of liver disease were considered in the model, excluding cardiovascular disease effects, ICER increased from the baseline case analysis to $16 305. Even when replacing with medical costs in Japan and U.S., it remained cost‐effective with the estimate below the countries' ICER threshold. Conclusions: Our study provides compelling evidence supporting the cost‐effectiveness of FIB‐4‐based screening the at‐risk population for advanced hepatic fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. A 3D direct coupling method for steady ship hydroelastic analysis
- Author
-
Lee, Ik Jae, Kim, Eun Soo, and Kwon, Sun Hong
- Published
- 2020
- Full Text
- View/download PDF
11. Sloshing assessment of the LNG floating units with membrane type containment system where we are?
- Author
-
Malenica, Sime, Diebold, Louis, Kwon, Sun Hong, and Cho, Dae-Seung
- Published
- 2017
- Full Text
- View/download PDF
12. Health Care Utilization and Direct Costs in Mild, Moderate, and Severe Adult Asthma: A Descriptive Study Using the 2014 South Korean Health Insurance Database
- Author
-
Lee, Yoo Ju, Kwon, Sun-Hong, Hong, Sung-Hyun, Nam, Jin Hyun, Song, Hyun Jin, Lee, Jong Seop, Lee, Eui-Kyung, and Shin, Ju-Young
- Published
- 2017
- Full Text
- View/download PDF
13. Experimental study on piston- and sloshing- mode moonpool resonances
- Author
-
Yang, Seung-Ho, Lee, Sang-Beom, Park, Jung-Ho, Han, Seung-Yoon, Choi, Young-Myung, Do, Jitae, Kwon, Sun-Hong, and Molin, Bernard
- Published
- 2016
- Full Text
- View/download PDF
14. Prediction of propagated wave profiles based on point measurement
- Author
-
Lee, Sang-Beom, Choi, Young-Myoung, Do, Jitae, and Kwon, Sun-Hong
- Published
- 2014
- Full Text
- View/download PDF
15. Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.
- Author
-
Oh, Byeong-Chan, Cho, Ae-Ryeo, Nam, Jin Hyun, Yang, So-Young, Kim, Min Ji, Kwon, Sun-Hong, and Lee, Eui-Kyung
- Subjects
ANAPLASTIC lymphoma kinase ,EPIDERMAL growth factor receptors ,NON-small-cell lung carcinoma ,TERMINATION of treatment ,ANAPLASTIC thyroid cancer - Abstract
Background: We aimed to examine whether patients with de novo and relapsed/progressed stage IIIB–IV non-small cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations have different prognoses. Methods: This retrospective study analyzed the Health Insurance Review and Assessment claims data in South Korea from 2013 to 2020. Patients with stage IIIB–IV NSCLC without EGFR or ALK mutations who received first-line palliative therapy between 2015 and 2019 were identified. Overall survival (OS), time to first subsequent therapy (TFST), and time to second subsequent therapy (TSST) were estimated using the Kaplan–Meier method. Multivariate Cox regression analysis was used to reveal the impact of de novo versus relapsed/progressed disease on OS. Treatment patterns, including treatment sequence, top five most frequent regimens, and time to treatment discontinuation, were described in both groups. Results: Of 14,505 patients, 12,811 (88.3%) were de novo, and 1,694 (11.7%) were relapsed/progressed. The median OS in the de novo group was 11.0 versus 11.5 months in the relapsed/progressed group (P = 0.002). The ongoing treatment probability was higher in relapsed/progressed patients than in de novo patients from 6.4 months since the initiation of first-line treatment (P < 0.001). Median TSST was shorter in the de novo group than in the relapsed/progressed group (9.5 vs. 9.9 months, P < 0.001). In multivariate analysis, de novo disease was associated with shorter OS (hazard ratio 1.07; 95% confidence interval 1.01–1.14). The overall treatment patterns for de novo and relapsed/progressed patients were similar. Conclusions: De novo patients had poorer OS and TSST after the initiation of palliative therapy than relapsed/progressed patients. These findings suggest that the stage of the disease at the time of initial diagnosis should be considered in observational studies and clinical trials as a prognostic factor. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Estimating the Total Societal Cost of a Hexavalent Vaccine versus a Pentavalent Vaccine with Hepatitis B in South Korea.
- Author
-
Min, Serim, Kwon, Sun-Hong, Lee, Yeon-Woo, Lee, Jung-Min, Bae, Eun Jin, and Lee, Eui-Kyung
- Subjects
HEPATITIS B vaccines ,COMMUNICABLE diseases ,HAEMOPHILUS influenzae ,VACCINES ,MEDICAL care - Abstract
In South Korea, the ready-to-use hexavalent vaccine (against diphtheria, tetanus, pertussis, poliovirus, Haemophilus influenzae type b, and hepatitis B) is not listed despite its facility of no need to reconstitute. It, therefore, has the potential to augment the efficiency of prevention against the six infectious diseases, and it may reduce vaccine-related errors of reconstitution when compared with the currently used vaccination scheme of the pentavalent vaccine with the additional shots against hepatitis B. Given the assumed clinical equivalence between the two vaccination schemes, a cost-minimization analysis has been performed from a societal perspective including all the medical and non-medical direct and indirect costs when vaccinating one birth cohort. The results indicate that the ready-to-use hexavalent vaccine induces a cost reduction of KRW 47,155 (USD36.22) per infant or 12,026 million Korean Won ($9,236,417) in total for the whole birth cohort with 260,500 children. Using the ready-to-use hexavalent vaccine causes a lower infection rate, has fewer vaccination sessions, and may save much time as compared with the current vaccination scheme in place. The ready-to-use hexavalent vaccine may, therefore, benefit the National Immunization Program by reducing the total societal costs of vaccination while improving convenience of infants, parents, and medical care professionals. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis.
- Author
-
Na, HyeJung, Kwon, Sun-Hong, Son, Kyung-Hwa, Baek, Youngsuk, Kim, Jiye, and Lee, Eui-Kyung
- Subjects
- *
MEDICAL personnel , *BIOSIMILARS , *RANDOMIZED controlled trials , *FILGRASTIM , *IMMUNE response - Abstract
Background: It is crucial that the safety profiles of biosimilars are similar to those of the original biologics. A better understanding of biosimilars and their relative safety and immunogenicity profiles are required for healthcare providers to prescribe them to patients with life-threatening cancer diseases who receive chemotherapies with potentially serious adverse events (AEs). Objectives: The purpose of this study was to collate and analyze currently available safety and immunogenicity outcomes of biosimilars used in oncology and compare their safety information with those of the original biologics. Methods: The MEDLINE and Cochrane Library databases were searched as at 28 February 2022. Four anti-cancer biosimilar molecules were considered: bevacizumab, trastuzumab, rituximab, and (peg)filgrastim. Through a systematic review, we selected the randomized controlled trials (RCTs) comparing safety outcomes between the biosimilars and original biologics of the four molecules. As safety outcomes, various treatment-emergent adverse events (TEAEs) were collated, such as any TEAE, serious AE, and TEAE higher than grade 3. A risk ratio (RR) per category of TEAE was estimated through a meta-analysis. A network meta-analysis (NMA) was also conducted to compare the safety among the biosimilar brands for TEAEs over 25% with higher variability in addition to the serious AE cases. Results: Forty-nine RCTs were identified. The results from the meta-analysis showed that the safety and immunogenicity profiles of all four biosimilar molecules are comparable with that of the original biologics at the TEAE level without statistically significant differences, except for diarrhea for (peg)filgrastim. The incidence of diarrhea with (peg)filgrastim was less than that with the original biologic (RR 0.66, 95% confidence interval 0.50–0.89). The NMA results showed similar safety profiles among the biosimilar brands for all four biosimilar molecules, except for the serious adverse event of a trastuzumab biosimilar (RR 0.296, 95% credible interval 0.109–0.840). Conclusion: The meta-analysis and NMA for all four biosimilars showed that the safety and immunogenicity profiles of biosimilar products in oncology are generally comparable with that of the original biologics at the TEAE level. However, additional evidence needs to be collected since several TEAEs of specific biosimilars were out of the equivalent range. The results of this study provide comparative safety information and a better understanding of oncology biosimilars for healthcare providers to prescribe them to patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Synthesis and properties of near IR induced self-healable polyurethane/graphene nanocomposites
- Author
-
Kim, Jin Tae, Kim, Byung Kyu, Kim, Eun Young, Kwon, Sun Hong, and Jeong, Han Mo
- Published
- 2013
- Full Text
- View/download PDF
19. Experimental study on moonpool resonance of offshore floating structure
- Author
-
Yang, Seung-Ho and Kwon, Sun-Hong
- Published
- 2013
- Full Text
- View/download PDF
20. Quantitative Benefit–Risk Assessment of COVID-19 Vaccines Using the Multi-Criteria Decision Analysis.
- Author
-
Son, Kyung-Hwa, Kwon, Sun-Hong, Na, Hye-Jung, Baek, Youngsuk, Kim, Inok, and Lee, Eui-Kyung
- Subjects
MULTIPLE criteria decision making ,COVID-19 vaccines ,DECISION making ,COVID-19 ,MEDICAL personnel - Abstract
In the early SARS-CoV-2 (COVID-19) pandemic, four major vaccines were approved despite limited efficacy and safety data through short regulatory review periods. Thus, it is necessary to assess the benefit-risk (BR) profiles of the COVID-19 vaccines. We conducted a quantitative BR assessment for four COVID-19 vaccines (mRNA-based: mRNA-1273 and BNT162b2; viral vector-based: Ad26.COV.2 and ChAdOx1-S) using multi-criteria decision analysis. Three benefit criteria and two risk criteria were considered: preventing COVID-19 infection for (1) adults aged ≥18 years; (2) seniors aged 60 years or older; and (3) severe COVID-19, adverse events (AEs), and serious AEs. Data were retrieved from clinical trials, observational studies, and county-specific AE monitoring reports. Based on the collected data, vaccines were scored for each criterion. 22 professionals weighted each criterion. The overall BR score was calculated using scores and weights. mRNA-1273 was the most preferred vaccine in pre-authorization and BNT162b2 in post-authorization. We found that the mRNA vaccine had a good balance between the benefits and risks. Using this BR assessment, the benefit-risk profile of COVID-19 vaccines can be updated with cumulated data. It will contribute to building evidence for decision making by policy makers and health professionals. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Visual Outcomes and Optical Quality of Accommodative, Multifocal, Extended Depth-of-Focus, and Monofocal Intraocular Lenses in Presbyopia-Correcting Cataract Surgery: A Systematic Review and Bayesian Network Meta-analysis.
- Author
-
Cho, Jeong-Yeon, Won, Yeo Kyoung, Park, Jongyeop, Nam, Jin Hyun, Hong, Ji-Yoon, Min, Serim, Kim, Nahyun, Chung, Tae-Young, Lee, Eui-Kyung, Kwon, Sun-Hong, and Lim, Dong Hui
- Published
- 2022
- Full Text
- View/download PDF
22. Experimental study on flow kinematics and impact pressure in liquid sloshing
- Author
-
Song, Youn Kyung, Chang, Kuang-An, Ryu, Yonguk, and Kwon, Sun Hong
- Published
- 2013
- Full Text
- View/download PDF
23. Optimal Indicator of Death for Using Real-World Cancer Patients' Data From the Healthcare System.
- Author
-
Jang, Suk-Chan, Kwon, Sun-Hong, Min, Serim, Jo, Ae-Ryeo, Lee, Eui-Kyung, and Nam, Jin Hyun
- Subjects
CANCER patients ,CANCER-related mortality ,NATIONAL health insurance ,OPERATIONAL definitions ,LOG-rank test ,THYROID gland ,LUNGS - Abstract
Background: Information on patient's death is a major outcome of health-related research, but it is not always available in claim-based databases. Herein, we suggested the operational definition of death as an optimal indicator of real death and aim to examine its validity and application in patients with cancer. Materials and methods: Data of newly diagnosed patients with cancer between 2006 and 2015 from the Korean National Health Insurance Service—National Sample Cohort data were used. Death indicators were operationally defined as follows: 1) in-hospital death (the result of treatment or disease diagnosis code from claims data), or 2) case wherein there are no claims within 365 days of the last claim. We estimated true-positive rates (TPR) and false-positive rates (FPR) for real death and operational definition of death in patients with high-, middle-, and low-mortality cancers. Kaplan−Meier survival curves and log-rank tests were conducted to determine whether real death and operational definition of death rates were consistent. Results: A total of 40,970 patients with cancer were recruited for this study. Among them, 12,604 patients were officially reported as dead. These patients were stratified into high- (lung, liver, and pancreatic), middle- (stomach, skin, and kidney), and low- (thyroid) mortality groups consisting of 6,626 (death: 4,287), 7,282 (1,858), and 6,316 (93) patients, respectively. The TPR was 97.08% and the FPR was 0.98% in the high mortality group. In the case of the middle and low mortality groups, the TPR (FPR) was 95.86% (1.77%) and 97.85% (0.58%), respectively. The overall TPR and FPR were 96.68 and 1.27%. There was no significant difference between the real and operational definition of death in the log-rank test for all types of cancers except for thyroid cancer. Conclusion: Defining deaths operationally using in-hospital death data and periods after the last claim is a robust alternative to identifying mortality in patients with cancer. This optimal indicator of death will promote research using claim-based data lacking death information. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Observability measures and their application to GPS/INS
- Author
-
Hong, Sinpyo, Chun, Ho-Hwan, Kwon, Sun-Hong, and Lee, Man Hyung
- Subjects
Global Positioning System -- Evaluation ,Inertial navigation systems -- Evaluation ,Mobile communication systems -- Research ,Wireless communication systems -- Research ,Global Positioning System ,Wireless technology ,Business ,Electronics ,Electronics and electrical industries ,Transportation industry - Abstract
In this paper, two observability measures are introduced for a discrete linear system. The degrees of observability of both the system and its subspaces can be examined with these measures. The measures are well conditioned to perturbation and applicable to multi-input/multi-output time-varying systems. The relations among observability, observability measures, error covariance, and the information matrix are presented. It is shown that the measures have direct connections with the singular value decomposition of the information matrix. In contrast to the error covariance, the measures are determined by the system model and independent of the initial error covariance. An example of the observability analysis of the Global Positioning System/Inertial Navigation System is given. The measures are confirmed to be less sensitive to the system model perturbation. It is also shown that the vertical component of the gyro bias can be considered unobservable with a tactical-grade inertial measurement unit for a horizontal constant-speed motion. Index Terms--Global Positioning System (GPS), inertial navigation, observability measure, singular value decomposition (SVD).
- Published
- 2008
25. Observability analysis of alignment errors in GPS/INS
- Author
-
Lee, Mun Ki, Hong, Sinpyo, Lee, Man Hyung, Kwon, Sun Hong, and Chun, Ho-Hwan
- Published
- 2005
- Full Text
- View/download PDF
26. Experimental study on the estimation of lever arm in GPS/INS
- Author
-
Hong, Sinpyo, Lee, Man Hyung, Chun, Ho-Hwan, Kwon, Sun-Hong, and Speyer, Jason L.
- Subjects
Levers -- Research ,Global Positioning System -- Analysis ,Global Positioning System ,Business ,Electronics ,Electronics and electrical industries ,Transportation industry - Abstract
Lever-arm uncertainty can be an important error source in the integration of the Global Positioning System (GPS) and inertial navigation system (INS). This paper presents both numerical and experimental studies on the estimation of the lever arm in the integration of a very-low-grade inertial measurement unit (IMU) with an accurate single-antenna GPS measurement system. Covariance simulation results showed that maneuvers play an important role on the estimation of the lever arm and attitude. The length of the lever arm has a rather insignificant effect on the estimation of these. Experimental tests conducted with a low-cost microelectromechanical system (MEMS) IMU and a carrier-phase differential GPS (CDGPS) measurement system showed that the lever arm can be estimated with centimeter-level accuracy. The test results confirmed that angular motions and horizontal accelerations improve the estimates of the lever arm and yaw angle, respectively. Index Terms--Global positioning system (GPS), inertial measurement unit (IMU), inertial navigation, inertial navigation system (INS), lever arm, observability.
- Published
- 2006
27. Observability of error states in GPS/INS integration
- Author
-
Hong, Sinpyo, Lee, Man Hyung, Chun, Ho-Hwan, Kwon, Sun-Hong, and Speyer, Jason L.
- Subjects
Antennas (Electronics) -- Research ,Inertial navigation -- Research ,Inertial navigation (Aeronautics) -- Research ,Global Positioning System -- Research ,Global Positioning System ,Business ,Electronics ,Electronics and electrical industries ,Transportation industry - Abstract
Observability properties of errors in an integrated navigation system are studied with a control-theoretic approach in this paper. A navigation system with a low-grade inertial measurement unit and an accurate single-antenna Global Positioning System (GPS) measurement system is considered for observability analysis. Uncertainties in attitude, gyro bias, and GPS antenna lever arm were shown to determine unobservable errors in the position, velocity, and accelerometer bias. It was proved that all the errors can be made observable by maneuvering. Acceleration changes improve the estimates of attitude and gyro bias. Changes in angular velocity enhance the lever arm estimate. However, both the motions of translation and constant angular velocity have no influence on the estimation of the lever arm. A covariance simulation with an extended Kalman filter was performed to confirm the observability analysis. Index Terms--Global Positioning System, GPS/INS, inertial measurement unit (IMU), inertial navigation, lever arm, observability.
- Published
- 2005
28. A Systematic Review of Economic Evaluations of Active Tuberculosis Treatments.
- Author
-
Byun, Joo-Young, Kim, Hye-Lin, Lee, Eui-Kyung, and Kwon, Sun-Hong
- Subjects
TUBERCULOSIS ,QUALITY-adjusted life years ,COST effectiveness ,MIDDLE-income countries ,PATIENT compliance ,DECISION trees - Abstract
Background: The disease burden of active tuberculosis (TB) is considerable, but systematic reviews of economic evaluations of active TB treatments are scarce. Methods: PubMed, EMBASE, and the Cochrane Library databases were used to search for articles on cost-effectiveness analysis or cost-utility analysis that economically evaluated active TB treatments, which were then systematically reviewed by two independent reviewers. We extracted vital components of the included studies, such as country, population, intervention/comparator, primary outcome, values of outcomes, thresholds, model type, time horizon, and health states included in the model. Results: Seventeen studies were included in this systematic review. Thirteen dealt with interventions of medications, and the remaining four compared care strategies. The Markov model was the most commonly used tool to compare medications, whereas studies on care plans mainly used decision trees. The most commonly used primary outcome was disability-adjusted life years, followed by quality-adjusted life years. For treatment-naïve TB, the 4-month regimen was more cost-effective than the 6-month regimen mainly in low- and middle-income countries. For multidrug-resistant TB, a bedaquiline-based regimen was cost-effective. For multidrug-resistant TB, decentralized care that employed the use of home or mobile devices was more cost-effective than hospital-based centralized care in low- and middle-income countries. Conclusion: New treatment strategies to improve therapeutic outcomes by enhancing treatment adherence, such as regimens with shorter durations (2 or 4 months) and decentralized care, or new anti-TB agents (e.g., bedaquiline) have been suggested as cost-effective interventions for active TB. This review provides information on the economic evaluation of active TB from good-quality studies, thus aiding the future economic evaluation of active TB. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Cost-Effectiveness of Adjuvant Immunotherapy With Cytokine-Induced Killer Cell for Hepatocellular Carcinoma Based on a Randomized Controlled Trial and Real-World Data.
- Author
-
Cho, Jeong-Yeon, Kwon, Sun-Hong, Lee, Eui-Kyung, Lee, Jeong-Hoon, and Kim, Hye-Lin
- Subjects
KILLER cells ,RANDOMIZED controlled trials ,HEPATOCELLULAR carcinoma ,OVERALL survival ,COST effectiveness - Abstract
Background: Studies using data from randomized controlled trials (RCTs) and real-world data (RWD) have suggested that adjuvant cytokine-induced killer (CIK) cell immunotherapy after curative treatment for hepatocellular carcinoma (HCC) prolongs recurrence-free survival (RFS) and overall survival (OS). However, the cost-effectiveness of CIK cell immunotherapy as an adjuvant therapy for HCC compared to no adjuvant therapy is uncertain. Methods: We constructed a partitioned survival model to compare the expected costs, life-year (LY), and quality-adjusted life-year (QALY) of a hypothetical population of 10,000 patients between CIK cell immunotherapy and no adjuvant therapy groups. Patients with HCC aged 55 years who underwent a potentially curative treatment were simulated with the model over a 20-year time horizon, from a healthcare system perspective. To model the effectiveness, we used OS and RFS data from RCTs and RWD. We estimated the incremental cost-effectiveness ratios (ICERs) and performed extensive sensitivity analyses. Results: Based on the RCT data, the CIK cell immunotherapy incrementally incurred a cost of $61,813, 2.07 LYs, and 1.87 QALYs per patient compared to no adjuvant therapy, and the estimated ICER was $33,077/QALY. Being less than the willingness-to-pay threshold of $50,000/QALY, CIK cell immunotherapy was cost-effective. Using the RWD, the ICER was estimated as $25,107/QALY, which is lower than that obtained using RCT. The time horizon and cost of productivity loss were the most influential factors on the ICER. Conclusion: We showed that receiving adjuvant CIK cell immunotherapy was more cost-effective than no adjuvant therapy in patients with HCC who underwent a potentially curative treatment, attributed to prolonged survival, reduced recurrence of HCC, and better prognosis of recurrence. Receiving CIK cell immunotherapy may be more cost-effective in real-world clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants.
- Author
-
Park, HyeJin, Park, Chan Mi, Woo, Jong-Min, Shin, Ju-Young, Lee, Eui-Kyung, and Kwon, Sun-Hong
- Subjects
MENTAL depression ,ANTIDEPRESSANTS ,MEDICAL care use ,MEDICAL care costs ,HOSPITAL care - Abstract
We aimed to determine the incidence of and identify the factors associated with treatment-resistant depression (TRD), psychiatric conditions, hospitalization, and cost in patients with major depressive disorder (MDD) who were treated using second-line strategies after an inadequate response to initial antidepressants (AD). Using South Korean National Health Insurance claims data (1 January 2013 to 30 June 2018), we conducted a retrospective cohort analysis in newly treated patients with MDD who subsequently switched or added AD, or added atypical antipsychotics (AAPs) as a second-line treatment. We assessed the incidence of treatment-resistant depression (TRD), psychiatric conditions, and hospitalization for the first 2 years and costs in the third year. Odds ratios (ORs) or relative ratios were estimated using logistic and linear regression models to identify the risk factors for clinical and economic outcomes. In 15,887 patients, the TRD was 16.81% during the 24-month follow-up period (14.14% in switching AD, 19.65% in adding AD, and 19.91% in adding AAP; p < 0.0001). When adding AD or AAP, the OR of TRD was 1.43 (95% confidence interval (CI): 1.30–1.56) and 1.42 (95% CI: 1.23–1.65), respectively, compared to switching AD. However, these factors were not associated with the incidence of psychiatric conditions. Adding AAP increased hospitalization (OR = 1.25, 95% CI: 1.11–1.41), the number of inpatient days by 2.57-fold (95% CI: 1.75–3.76), and cost by 1.20-fold (95% CI: 1.02–1.40), compared to switching AD; adding AD did not show a significant association with these outcomes. In patients with MDD with inadequate responses to initial AD, TRD still occurred after subsequent treatments according to clinical guidelines. Since the effectiveness of second treatment strategies can differ in reality, further analysis of the clinical and economic evidence regarding second treatment strategies, such as adding AD or AAP, is needed using real-world data. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea.
- Author
-
Park, Jae-A, Lee, Min-Young, Nam, Jin Hyun, Shin, Ju-Young, Wood, Robert, Holbrook, Tim, and Kwon, Sun-Hong
- Subjects
ANTIRHEUMATIC agents ,TUMOR necrosis factors ,RHEUMATOID arthritis ,PROPORTIONAL hazards models ,NATIONAL health insurance ,PERSISTENCE ,RESEARCH ,RESEARCH methodology ,RETROSPECTIVE studies ,EVALUATION research ,MEDICAL cooperation ,COMPARATIVE studies - Abstract
Aims: We aimed to assess treatment persistence of tumor necrosis factor (TNF) inhibitors and non-TNF inhibitors in two groups of rheumatoid arthritis (RA) patients: biologic disease-modifying antirheumatic drug (bDMARD) initiators and switchers.Patients and methods: This retrospective cohort study utilized a national health insurance claims database. Patients aged ≥18 years initiating/switching bDMARD between 1 December 2013 and 31 December 2014, the index period, were followed for 12 months. Initiators who began treatment with a bDMARD during the index period were defined as having no bDMARD prescriptions for the previous year. Switchers who changed treatment from the previous bDMARD to the index bDMARD were defined as having different bDMARDs during the index period. Treatment persistence rates during the follow-up period were measured, and factors associated with non-persistence were assessed with the Cox proportional hazard model.Results: Of 2684 patients, treatment persistence rates were the highest for abatacept in initiators (69.3%) and tocilizumab in switchers (77.0%), while adalimumab showed the lowest persistence rates for both initiators and switchers (48.2%, 28.8%), followed by etanercept (51.3%, 41.0%). Adalimumab and etanercept were significantly more likely to show non-persistence (HR 1.58, 95% CI 1.27-1.96; HR 1.42, 95% CI 1.14-1.76) compared to infliximab for initiators, while tocilizumab was significantly more likely to show persistence (HR 0.411, 95% CI 0.206-0.819) in switchers.Conclusions: Non-TNF inhibitors showed higher persistence rates than TNF inhibitors in South Korean RA patients, and tocilizumab especially was associated with higher persistence in patients with inadequate response to TNF inhibitors. Good persistence with non-TNF inhibitors indicates the potential for long-term efficacy as first-line treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer.
- Author
-
Lee, Ju-Eun, Kwon, Sun-Hong, Kwon, Swan, Jung, Hye-In, Nam, Jin Hyun, and Lee, Eui-Kyung
- Published
- 2023
- Full Text
- View/download PDF
33. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.
- Author
-
Kwon, Sun-Hong, Park, Sun-Kyeong, Byun, Ji-Hye, and Lee, Eui-Kyung
- Subjects
ANTINEOPLASTIC agents ,CUSTOMER satisfaction ,COST effectiveness ,DECISION making ,FOCUS groups ,MEDICAL needs assessment ,MEDICAL personnel ,HEALTH policy ,HEALTH insurance reimbursement ,TUMORS ,ECONOMICS - Abstract
Introduction: In order to look beyond the cost-effectiveness analysis, this study used a multi-criteria decision analysis (MCDA), which reflects societal values with regard to reimbursement decisions. This study aims to elicit societal preferences of the reimbursement decision criteria for anti cancer drugs from public and healthcare professionals.Methods: Eight criteria were defined based on a literature review and focus group sessions: disease severity, disease population size, pediatrics targets, unmet needs, innovation, clinical benefits, cost-effectiveness, and budget impacts. Using quota sampling and purposive sampling, 300 participants from the Korean public and 30 healthcare professionals were selected for the survey. Preferences were elicited using an analytic hierarchy process.Results: Both groups rated clinical benefits the highest, followed by cost-effectiveness and disease severity, but differed with regard to disease population size and unmet needs. Innovation was the least preferred criteria.Conclusions: Clinical benefits and other social values should be reflected appropriately with cost-effectiveness in healthcare coverage. MCDA can be used to assess decision priorities for complicated health policy decisions, including reimbursement decisions. It is a promising method for making logical and transparent drug reimbursement decisions that consider a broad range of factors, which are perceived as important by relevant stakeholders. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
34. A benefit-risk assessment model for statins using multicriteria decision analysis based on a discrete choice experiment in Korean patients.
- Author
-
Ji-Hye Byun, Sun-Hong Kwon, Ji-Hye Ha, Eui-Kyung Lee, Byun, Ji-Hye, Kwon, Sun-Hong, Ha, Ji-Hye, and Lee, Eui-Kyung
- Subjects
STATINS (Cardiovascular agents) ,DECISION making ,MULTIPLE criteria decision making ,CHOLESTEROL ,HEPATOTOXICOLOGY - Abstract
Purpose: The benefit-risk balance for drugs can alter post approval owing to additional data on efficacy or adverse events. This study developed a quantitative benefit-risk assessment (BRA) model for statins using multicriteria decision analysis with discrete choice experiments and compared a recent BRA with that at the time of approval.Patients and Methods: Following a systematic review of the literature, the benefit criteria within the statin BRA model were defined as a reduction in the plasma low-density lipoprotein cholesterol level and a reduction in myocardial infarction incidence; the risk criteria were hepatotoxicity (Liv) and fatal rhabdomyolysis (Rha). The scores for these criteria were estimated using mixed treatment comparison methods. Weighting was calculated from a discrete choice experiment involving 203 Korean patients. The scores and weights were integrated to produce an overall value representing the benefit-risk balance, and sensitivity analyses were conducted.Results: In this BRA model, low-density lipoprotein (relative importance [RI]: 37.50%) was found to be a more important benefit criterion than myocardial infarction (RI: 35.43%), and Liv (RI: 16.28%) was a more important risk criterion than Rha (RI: 10.79%). Patients preferred atorvastatin, and the preference ranking of cerivastatin and simvastatin was switched post approval because of the emergence of additional risk information related to cerivastatin.Conclusion: A quantitative statin BRA model confirmed that the preference ranking of statins changed post approval because of the identification of additional benefits or risks. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
35. Effects of chain extender in biodegradable polyurethane foams.
- Author
-
Kang, Sung Moon, Kang, Moo Seok, Kwon, Sun Hong, Park, Hyun, and Kim, Byung Kyu
- Subjects
POLYURETHANES ,POLYOLS ,GLYCERIN ,GLASS transition temperature ,TOLUENE diisocyanate - Abstract
Molded flexible polyurethane (PU) foams were synthesized from a starch/petroleum based polyol, 2,4/2,6-toluene diisocyanate (TDI-80), using a one shot method with water as the blowing agent. The effects of chain extender type [starch (S series), diethanolamine (DEA, D series), glycerol (G series)] and content (0, 2, 5, 10 pphr) were extensively studied. The rate of foam formation, density, compression strength, glass transition temperature (T
g ) and rubbery modulus of the foam increased with the addition and increasing content of extender. At the same extender content, DEA showed the highest of these properties, while starch showed the lowest. The rate of biodegradation in a buffer solution decreased with the addition of DEA and glycerol, due to the increased crosslinking density and hard segment content, but increased with starch, owing to its biodegradability. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
36. Sources of the Measurement Error of the Impact Pressure in Sloshing Experiments.
- Author
-
Kim, Dong Hwi, Kim, Eun Soo, Shin, Sung-chul, and Kwon, Sun Hong
- Subjects
MEASUREMENT errors ,PRESSURE ,PRESSURE sensors ,SURFACE pressure - Abstract
Sloshing experiments have increasingly received academic attention. Understanding the measurement errors in the sloshing impact pressures is an important parts of the sloshing experiments since these errors, which arise from experimental conditions, affect the subsequent results. As part of the research on the sources of the measurement errors, focused on the effects of surface conditions of pressure sensors on the measurement of impact pressures. Thirty-six integrated circuit piezoelectric pressure sensors were placed on the upper surfaces of a two-dimensional tank to measure the sloshing impact pressures under surge or pitch motions. For each motion, the experimental conditions were divided in two based on whether the surfaces of the sensors were dry or wet. The peak pressures of each test were measured as twenty repeated experiments to ensure reliability. The flow in the tank was visualized using a high-speed camera to observe and analyze macroscopic and microscopic phenomena along the sensor surface. Thermal shock effects were confirmed by varying the experimental temperature and that of the sensor surface. The effects of the wet surface and droplets formed on the sensor surface on pressure measurements are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. Clinical impact and economic burden of post-transplant infections following heart transplantation: A retrospective nationwide cohort study.
- Author
-
Jang, Suk-Chan, Oh, Byeong-Chan, Nam, Jin Hyun, Lee, Eui-Kyung, Kim, Hye-Lin, and Kwon, Sun-Hong
- Subjects
- *
HEART transplantation , *HEART transplant recipients , *COHORT analysis , *ECONOMIC impact , *RESPIRATORY infections - Abstract
Post-transplant infections are associated with high mortality rates. This retrospective nationwide cohort study examined the incidence and risk factors of infections requiring hospitalization after heart transplantation and the associated economic burden. The entire heart transplant recipients' data from the Korean Health Insurance Review and Assessment Service between 2013 and 2020 was used. We estimated the annual incidence of post-transplant infections and adjusted incidence rate ratios (aIRR) of risk factors for reported infections using the poisson generalized linear model. Among 1,030 heart transplant recipients (324 with and 706 without post-transplant infections), 0.45 post-transplant infections were reported annually, with respiratory tract infections constituting the highest proportion (0.16). The risk of post-transplant infections was high in recipients with renal failure (aIRR = 1.35; 95% confidence interval [CI], 1.05–1.75) or nosocomial infection (aIRR = 1.47; 95% CI, 1.15–1.87). Combination regimens, including mammalian target of rapamycin inhibitor (mTORi), did not differ significantly from the standard 3 drug regimen (aIRR = 1.16; 95% CI, 0.80–1.67). The risk of death was higher among recipients with post-transplant infections than in uninfected recipients (adjusted hazard ratio = 4.59; 95% CI, 2.19–9.65). The mean follow-up cost per patient per month was 2-fold higher in recipients with post-transplant infections than in uninfected recipients ($5,096 and $2,532, respectively; p <.001). mTORi combination, which reportedly maintains renal function, can be considered, as it does not increase the infection risk. Post-transplant infections present clinical and economic burdens, warranting careful observation of at-risk patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.